Genesystem진시스템

Genesystem's revenue has collapsed while losses remain deep, and the company is pursuing a merger and convertible bond financing.

Genesystem, a Korean maker of molecular diagnostic systems and test kits, reported trailing twelve-month revenue of about ₩1.0B against an operating loss of about ₩7.9B through H1 2026. The share price is ₩4,050, down 34.3% over one year but up 12.8% over three months, with a market value of about ₩34.5B. Recent filings center on a merger decision, a subsidiary dissolution event, a convertible bond issue and asset transfers.

What stands out

• Revenue fell from ₩3.65B in 2022 and ₩1.21B in 2024 to ₩381M in 2025, and TTM revenue is about ₩1.0B.
• Operating losses have persisted every year since 2022, with a TTM operating margin of -777.4% and free cash flow of about -₩8.8B.
• Cash of about ₩4.1B sits against borrowings of about ₩3.7B, and liabilities are 51.9% of equity.
• The company has no dividend, and the price-to-book ratio of 2.9 is shown without a usable earnings multiple because earnings are negative.
• Recent filings include a merger decision (amended 16 Oct 2026), a convertible bond issue and results, and a debt guarantee for another party. The data contains no news headlines to add context.

What to watch

• Details and timing of the merger, including the subsidiary dissolution event, which the filings do not fully explain in the data provided.
• Whether the convertible bond financing and cash balance are enough to cover the ongoing negative free cash flow.
• The next annual or half-year results, which will show whether revenue can recover from its 2025 low.